Note: Descriptions are shown in the official language in which they were submitted.
CA 02541217 2006-03-31
WO 2005/070335 PCT/US2004/038383
TITLE
STENT REDUCING SYSTEM
CROSS-REFERENCE TO RELATED APPLICATIONS
Not Applicable
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
Not Applicable
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates generally to stents, stent loading, stent
contracting and stent delivery systems and their respective methods of use.
Some
embodiments of the invention are more specifically directed to stent loading
and
crimping systems which are configured for reduced frictional interface between
a stent
and one or more system component which contact the stent during the crimping
and
loading process.
Description of Related Art
A stent is a generally tubular device that is used to support a bodily lumen.
A stent is typically delivered to a desired bodily location via a catheter.
Often the stent is
loaded onto a portion of the catheter, such as a balloon or other region of
the catheter
shaft. In some stent delivery systems the stent is crimped to the catheter in
order to
minimize the profile of the stent on the catheter and to prevent undesired
movement of
the stent relative to the catheter shaft.
A number of techniques for loading and contracting a stent to a catheter
shaft or balloon are used. One such technique that is commonly used in the
radiological
suite involves hand crimping the stent to the balloon. A stent is placed over
an uninflated
balloon and then squeezed with the fingers until the stent is in intimate
contact with the
uninflated balloon. The technique is highly operator dependent and can affect
stent
1
CA 02541217 2011-07-25
profile and stent placement with respect to the balloon and radiopaque
markers. It can
also affect the dilatation length of the stent and lead to pinching of the
balloon.
Other techniques for crimping stents involve the use of mechanical
devices for crimping stents. Mechanical stent crimpers have been disclosed in
a number
of patents including US 6,387,118; US 6,360,577; US 6,108,886; US 6,092,273;
US
6,082,990 ; US 6,074,381; US 6,063,102 and US 5,992,000. Mechanical stent
crimpers
have also been disclosed in US 6,352,547; US 6,387,117; and US 6,769,161.
In many current stent loading operations particularly those involving self-
expanding nitinol or shape memory stents the stent is dipped or sprayed with
liquid
nitrogen or other cooling agent in order for the stent to achieve a
martensitic state. While
in the martensitic state the stent is constrained via a crimper or other
reducing device. In
some cases the crimper comprises an adjustable stent diameter reducing chamber
or
opening through which the stent is advanced in order to uniformly reduce or
compress
the stent about its circumference.
Stent crimpers may have a variety of configurations and mechanisms for
providing the stent diameter reduction chamber. For example, an iris type
chamber
wherein a plurality of members or blades are moved relative to the stent to
reduce or
expand the diameter of the chamber is described in U.S. 6,360,577, a crimper
having a
chamber defined by a plurality of member which extend inward to contract the
chamber
in a "star" or other geometric configuration is described in U.S. 6,168,921, a
crimper
having a pair of jaws or members that are moved relative to one another to
reduce or
expand the diameter of the chamber is described in U.S. 6,387,117, and a
crimper having
one or more conical apertures which at least partially define the chamber is
described in
U.S. 5,992,000. Crimpers having other configurations are also known.
In many crimper assemblies a mandrel or push rod is utilized to drive the
stent through the closed iris into a stent delivery mechanism such as a
catheter.
In many crimper designs however, the crimping members or blades will
come into direct contact with the stent being crimped as the iris is closed
radially inward
about the stent. After the stent has been reduced in diameter, in many
instances the
2
CA 02541217 2011-07-25
blades are kept in direct contact with the stent in order to keep the stent in
the reduced
state prior to loading of the stent onto a catheter or other delivery system.
The stent is
then transferred from the iris onto the delivery system by advancing a push
rod or
mandrel through the closed iris. In order to expel the stent from the iris the
longitudinal
force exerted on the stent by the mandrel must be sufficient to disengage the
stent from
its contact with the blades. If the force exerted on the stent by the mandrel
is greater than
the column strength of the stent the stent will buckle thereby leading to an
unsuccessful
loading of the stent. Unfortunately, such excessive force is often required to
remove the
stent from the crimper.
In addition to potentially buckling the stent, the force exerted by direct
contact of the crimper blades on the stent as well as the act of pushing the
stent out of the
iris may have significant impact on any coating the stent may have even if the
force is not
excessive. For example where the stent includes one or more therapeutic
coatings (i.e. a
drug coated stent), direct contact of the stent by the blades during
reduction, and/or the
frictional interface of the blades and the stent during expulsion of the stent
from the iris,
may result in impairment of the coating thus reducing or negating its
effectiveness.
In light of the above there is a need to provide stent reducing/loading
systems with the capability to reduce and expel a stent, especially those
stents having a
therapeutic coating, from the reducing mechanism with reduced force and
preferably with
reduced contact between the stent and the reducing mechanism and/or push rod
or
support mandrel.
Without limiting the scope of the invention a brief summary of some of
the claimed embodiments of the invention is set forth below. Additional
details of the
summarized embodiments of the invention and/or additional embodiments of the
invention may be found in the Detailed Description of the Invention below.
A brief abstract of the technical disclosure in the specification is provided
as well. The abstract is not intended to be used for interpreting the scope of
the claims.
3
CA 02541217 2006-03-31
WO 2005/070335 PCT/US2004/038383
BRIEF SUMMARY OF THE INVENTION
The present invention is particularly concerned with the crimping and
otherwise reducing in size of stents, including bare or coated stents of any
configuration
or expansion type, including inflation expandable stents, self-expanding
stents, hybrid
expandable stents, etc. For the purpose of this disclosure, it is understood
that the term
`stent' includes stents, stent-grafts, grafts and vena cava filters and other
implantable
medical devices for luminal support. It is also understood that the term
`crimping' refers
to a reduction in size or profile of a stent and `crimper' refers to devices
for
accomplishing such reduction in size or profile of a stent.
The present invention is embodied in a variety of forms. In at least one
embodiment the invention is directed to a stent reducing and/or loading
mechanisms such
as stent crimpers and associated reducing and loading tools. In some
embodiments a
crimper comprises a contractible opening or stent reduction chamber defined by
two or
more members which define the opening. In at least one embodiment the chamber
is an
iris or other contractible and expandable opening defined by a plurality of
moveable
contacting members or blades. The chamber has a variable diameter and may be
adjusted
between an open diameter and a closed diameter. The crimper defines one or
more
spaces adjacent to each blade of the chamber. A fluid, such as a liquid or gas
may be
passed through one or more of theses spaces and into the chamber. The fluid
forms a
boundary layer between the blades and the stent to reduce friction between the
blades and
the stent. In some embodiments the presence of the fluid boundary layer
minimizes
adherence of the stent to the blades of the chamber.
In at least one embodiment the fluid forins a fluid bearing between the
stent and the blades. The fluid bearing minimizes or eliminates direct contact
between
the stent and the crimping blades.
In at least one embodiment the fluid is cooled to a sufficiently low
temperature so as to maintain a shape memory stent in a martensitic state,
thereby
inhibiting the stent composition form transitioning to an austenitic phase. In
some
embodiments the fluid is cooled to a predetermined temperature sufficient to
provide the
stent with a phase transformation from austenitic to martensitic.
In at least one embodiment an existing crimper is provided with a fluid
4
CA 02541217 2006-03-31
WO 2005/070335 PCT/US2004/038383
source to inject fluid into the stent reduction chamber through the existing
gaps between
the blades. In some embodiments the blades of a crimper are modified to
provide slots
through which fluid may be channeled into the chamber.
In at least one embodiment the fluid is air.
In at least one embodiment the invention comprises a mandrel which
supports the stent as it is advanced through the stent diameter reducing
chamber. In
some embodiments the mandrel has a stepped diameter which allows the stent to
be
secured at one or more of its proximal and distal ends by a raised diameter
portion or
collar of the mandrel. In some embodiments the distal end of the mandrel is
tapered to
facilitate alignment of the mandrel with a stent delivery system such as a
catheter. In
some embodiments the mandrel is provided with a polymer coating.
In at least one embodiment the mandrel defines a mandrel lumen. A fluid
may be passed through the lumen to the stent and/or the chamber. In some
embodiments
the fluid passed through the lumen is liquid nitrogen, chilled air or a
similar cooling
composition.
In at least one embodiment the crimper defines a stepped diameter
chamber. When the chamber is in the closed position about the stent a delivery
system,
such as a catheter, may be partially inserted into the larger diameter stepped
region of the
closed chamber in order to precisely align the stent and/or mandrel with the
delivery
system.
In at least one embodiment of the invention a vibratory mechanism is in
communication with one or more components of a stent crimper and/or loading
mandrel.
The vibratory mechanism may apply vibratory energy to the crimper, loading
mandrel,
stent, and/or delivery system to aid in minimizing frictional interface
therebetween. In
some embodiments vibratory energy may also be selectively applied to the
crimper
following contraction of the stent to aid in releasing the stent from the
blades. In some
embodiments vibratory energy may also be selectively applied to the mandrel
once the
stent is properly positioned within the delivery system in order to aid in
releasing the
stent from the mandrel. In some embodiments the vibratory energy is delivered
at an
ultrasonic frequency.
CA 02541217 2006-03-31
WO 2005/070335 PCT/US2004/038383
These and other embodiments which characterize the invention are
pointed out with particularity in the claims annexed hereto and forming a part
hereof.
However, for a better understanding of the invention, its advantages and
objectives
obtained by its use, reference should be made to the drawings which form a
further part
hereof and the accompanying descriptive matter, in which there is illustrated
and
described embodiments of the invention.
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
A detailed description of the invention is hereafter described with specific
reference being made to the drawings in which:
FIG. 1 is a perspective view of an embodiment of the invention wherein
the stent reduction chamber is shown in the open or pre-reduction state.
FIG. 2 is a perspective view of the embodiment shown in FIG. 1 wherein
the chamber is shown in the closed or reduced state.
FIG. 3 is a partial cross-sectional side view of the embodiment shown in
FIG. 2.
FIG. 4 is a partial close-up view of a portion of the embodiment shown in
FIG. 2 and 3.
FIG. 5 is a partial close-up view of the embodiment depicted in FIG.4
illustrating the fluid bearing between the stent and crimper.
FIG. 6 is a partial cross-sectional end view of an iris configuration of the
embodiment shown in FIGs 2 and 3.
FIG. 7 is a partial cross-sectional end view of an iris configuration of the
embodiment shown in FIGs 2 and 3 wherein the crimping blades are provided with
fluid
passages.
FIG. 8 is a partial close-up, cross-sectional side view of the embodiment
shown in FIGs. 2 and 3 wherein the stent is shown being expelled from the
crimper using
a push rod or mandrel.
FIG. 9 is a partial close-up view of the embodiment depicted in FIG.8
illustrating the loading of a stent into a stent delivery catheter wherein the
crimper is
provided with a stepped diameter reducing chamber.
6
CA 02541217 2006-03-31
WO 2005/070335 PCT/US2004/038383
FIG. 10 is a partial cross-sectional side view of the embodiment shown in
FIG. 8 wherein the stent is mounted on a configuration of the mandrel during
the
crimping process.
FIG. 11 is a partial cross-sectional side view of the embodiment shown in
FIG. 8 wherein the stent is mounted on a configuration of the mandrel during
the
crimping process.
FIG. 12 is a partial cross-sectional side view of the embodiment shown in
FIG. 8 wherein the stent is mounted on a configuration of the mandrel during
the
crimping process.
DETAILED DESCRIPTION OF THE INVENTION
As is depicted in the various FIGs. 1-12, the present invention comprises
embodiments which address the shortcomings described above.
As indicated above, the present invention is embodied in a variety of
forms. In at least one embodiment, such as for example in the embodiment
depicted in
FIG. 1, the invention is directed to a radial stent reducing assembly or
crimper 10.
Crimper 10 may have any configuration of contacting members and/or any
configuration
of stent diameter reducing chamber, such as has been described above.
In the embodiment shown, crimper 10 is provided with a plurality of stent
reducing members or blades 12 which define a stent reduction chamber 14 into
which a
stent or other medical device 16 is positioned in order to reduce the stent 16
from an
unreduced diameter state, such as is shown in FIG. 1 to a reduced diameter
state as is
shown in FIG. 2. Unlike many prior stent crimping devices, the crimper 10 in
the
embodiment shown in FIGs. 1-3 is constructed and arranged to form a fluid
bearing 20
between the blades 12 and the stent 16 during the crimping or reducing
process. The
fluid bearing 20 is formed by a fluid such as air, water, coolant, etc.,
indicated by avows
22 in FIG. 3, which is injected into the chamber 14 through the blades 12 or
through one
or more passages therein and/or therebetween, such as is shown in FIG. 3. The
presence
of a fluid bearing 20 between the blades 12 and the stent 16 ensures that the
stent 16 is
not directly contacted by the blades 12 of the closing chamber 14 during the
crimping
process.
7
CA 02541217 2006-03-31
WO 2005/070335 PCT/US2004/038383
Blades 12 may be constructed from one or more metals, polymers or
combinations thereof.
As is shown in FIGs. 1-2, the fluid bearing 20 is established by injecting
fluid 22 from a fluid source 30 into the crimper housing 18 by one or more
ports 24.
Each port 24 is in fluid communication with the one or more fluid passages 26
between
and/or within each blade 12. Each fluid passage 26 leads into the chamber 14.
By
injecting fluid into the chamber 14 under pressure, and substantially
maintaining the fluid
pressure within the chamber 14 during the crimping process, a fluid bearing 20
is formed
between the blades 12 and the stent 16. In some embodiments fluid pressure is
about 2
to about 20 psi.
In order to maintain the fluid pressure necessary to form the fluid bearing
20, the open ends 32 of the chamber 14 may be provided with one or more
removable
end seal members 34, such as is shown in FIG. 3. Seal members 34, be
configured to
include a variety of mechanisms. For example each member 34 may be configured
as a
simple fluid tight seal to prevent any fluid from escaping the chamber 14
during the
crimping process. In some embodiments the members 34 may define a labyrinth
passage
which allows fluid 22 to escape the contracting chamber at a predetermined
rate, in order
to maintain a fluid bearing having a substantially constant pressure. In some
embodiments the members 34 may define an opening therethrough which has a
diameter
less than that of the stent in the reduced state, in order to allow fluid 22
to pass from the
chamber 14 which retaining the stent 16 therein. The members 34 may include
one or
more of the mechanisms described above as well as other mechanisms, such as
adjustable
valves, ports, seals, etc. for maintaining and/or regulating fluid pressure.
In some embodiments fluid 22 is injected into the housing 18 through one
or more ports 24. In at least one embodiment, at least one port may be opened
following
the crimping process to allow the fluid 22 of the fluid bearing 20 to be
purged from the
chamber 14.
In some embodiments the fluid 22 is a fluid or combination of fluids
including, but not limited to air, carbon dioxide, water, nitrous oxide,
nitrogen gas or any
other fluid for use in forming a fluid bearing 20 between two surfaces. In at
least one
embodiment fluid 22 is a bead-like substance that acts in the manner of a ball
bearing. In
8
CA 02541217 2006-03-31
WO 2005/070335 PCT/US2004/038383
some embodiments fluid 22 may remain on the stent surface post loading.
In some embodiment fluid 22 not only provides the fluid bearing 20, but
where the fluid is cooled or is provided with a sufficiently low temperature,
the fluid also
acts to maintain a stent 16 constructed of a shape memory material, such as
for example
nitinol or other shape memory metals or polymers, in a martensitic state,
thereby
inhibiting the stent composition form transitioning to an austenitic phase. In
some
embodiments the fluid is cooled to a predetermined temperature sufficient to
provide the
stent with a phase transformation from austenitic state to martensitic state.
In some
embodiments the temperature is sufficient to reach the Mfof Nitinol or other
material
from which the stent is constructed. In at least one embodiment the
temperature of the
fluid 22 is about -60 to about -80 Celsius. In an embodiment where the stent
16 is
constructed of one or more polymers the fluid 22 has a temperature of just
below the
melting point of the polymer material.
As indicated above, fluid 22 is injected into the chamber 14 through one
or more fluid passages 26. In some embodiments, fluid passages 26 may be
defined by
the space 28 between longitudinally displaced blades 12 such as are shown n
FIG. 3. In
some embodiments the blades 12 are sized and shaped to define a space 28
radially
between each blade 12 such as is shown in FIG. 4. When the blades 12 are
contracted to
reduce the chamber 14, such as is shown, the spaces 28 act as fluid passages
26 to
transport fluid 22 into the chamber 14. In the configuration shown in FIG. 4,
the fluid
22 form a fluid bearing 20 that effectively extends from the chamber 14 into
the fluid
passages 26, such as is best shown in FIG. 5. As a result, in this embodiment,
wear
resulting from contact between the blades is avoided as the fluid bearing 20
acts to not
only prevent contact between the stent 16 and blades 12, but between the
individual
blades as well.
As indicated above, the use of fluid 22 in forming a fluid bearing may be
used in a variety of crimpers 10. In the embodiment shown in FIG. 6 for
example, the
crimper 10 is provided with an annular fluid passage 26 which is in fluid
communication
with four fluid ports 24. The fluid 22 is injected into the passage 26 and
flows into the
chamber 14 via the spaces 28 between the blades 12, which in some embodiments'
may
be provided for as a result of the natural tolerances resulting from the
blades'
9
CA 02541217 2006-03-31
WO 2005/070335 PCT/US2004/038383
construction. In at least one embodiment, an example of which is shown in FIG.
7 one or
more of the blades 12 is especially constructed to include fluid passages 26
between the
adjacent blades 12.
As is shown in FIG. S, in some embodiments a push rod or mandrel 40
may be inserted into an end 32 of the chamber 14 during or subsequent to the
reduction
of the stent 16. The mandrel may supplement or replace one of the seal members
in
order to ensure that the formation and performance of the fluid bearing 20 is
not
compromised by the mandrel's use. In order to maximize the benefit of reducing
contact
between the blades 12 and the stent 16, in some embodiments the fluid bearing
20 is
maintained even during expulsion of the stent 16 from the chamber 14 by
advancing the
mandrel 40 therethrough.
As is shown in FIG. 9, in some embodiments, the reduced diameter stent
16 is loaded directly onto a catheter or other stent delivery system 50 by
pushing the stent
16 through the chamber 14 and directly into the catheter's protective housing
or sheath
52. In order to facilitate the loading of the reduced stent 16 onto the
catheter 50, in some
embodiments the crimper 10 may have a chamber 14 with a stepped diameter, to
allow
the catheter 50 to be partially inserted within the chamber 14.
The catheter receiving region 54 of the stepped diameter chamber 14 has a
greater diameter than the stent reducing region 56. In at least one embodiment
the inner
diameter 58 of the catheter 50 is at least as large as the diameter of the
stent reducing
region 56 of the chamber 14. When a catheter 50 is engaged to the crimper 10
in the
manner shown in FIG. 9, the stent 16 may be advanced directly into the sheath
52,
without compromising the fluid bearing 20. Once the stent is loaded onto the
catheter 50
the fluid bearing may be maintained within the catheter 50, or the fluid may
be
withdrawn from the catheter 50 by application of a vacuum or other mechanism.
In some embodiments, some examples of which are depicted in FIGs. 10-
12, the stent 16 is reduced within the crimper 10 while mounted on a portion
of the
mandrel 40. In the embodiment shown in FIG. 10, the mandrel 40 has a tapered
distal
end portion 42 which has a diameter less than that of the inner diameter 58 of
a catheter
50. As a result, the mandrel 40, including the reduced diameter stent 16 may
be readily
advanced into the catheter 50 with minimal or no contact between the stent 16
and the
CA 02541217 2006-03-31
WO 2005/070335 PCT/US2004/038383
sheath 52. In some embodiments the mandrel 40 further comprises a proximal end
portion 44 which defines an annular seal 46, the annular seal 46 has a
diameter larger
than that of the chamber 14 in the closed or reduced configuration. As a
result, the
annular seal 46 may supplement or replace the need for a fluid seal member 34
at one end
32 of the chamber 14.
In the embodiment shown in FIG. 11, both the proximal end portion 44
and the distal end portion 42 of the mandrel 40 each comprise an annular seal
46. Each
annular seal 46 acts as a fluid seal member, as described above. In at least
one
embodiment, the fluid bearing 20 forms not only between the blades 12 and the
stent 16,
but also between the portion of the mandrel 40 about which the stent 16 is
disposed and
the stent 16. Such a dual layer fluid bearing 20 protects both the inside
surface 60 and
outside surface 62 of the stent 16 from extraneous contact.
In at least one embodiment, such as is shown in FIG. 12, the mandrel 40
may define a fluid injection lumen 70 into which a fluid 22a maybe injected.
Mandrel
40 may further define one or more perfusion ports, openings, perforations or
pores 72
through which the fluid 22a may pass from the lumen 70 and into the chamber
14. Fluid
22a injected into the chamber in this manner may be used to assist in forming
the fluid
bearing 20, and particularly a dual layer fluid bearing such as previously
discussed. In
some embodiments the fluid 22a passively, by cooling the mandrel 40, or
actively, by
directly flowing onto the stent 16, cools the stent 16 to a temperature
sufficient to provide
the stent with a phase transformation from austenitic to martensitic.
In such an embodiment the fluid 22a is cooled air, liquid nitrogen (nitrous
oxide) or another suitable coolant.
In some embodiments, one or more blades 12, the mandrel 40 and/or the
fluid 22 and/or 22a by be imparted with an ultrasonic or other form of
vibratory energy in
order to further facilitate minimization of the frictional interface between
the stent 16 and
the crimper 10 or any of its components.
In at least one embodiment the stent 16 as shown in any of the various
FIGs. 1-12 may include one or more coatings and/or other delivery mechanisms
which
comprise one or more therapeutic agents, cellular materials, polymeric agents,
drugs, etc.
11
CA 02541217 2006-03-31
WO 2005/070335 PCT/US2004/038383
A therapeutic agent may be a drug, a non-genetic agent, a genetic agent,
etc. Some examples of suitable non-genetic therapeutic agents include but a re
not
limited to: anti-thrombogenic agents such as heparin, heparin derivatives,
urokinase, and
PPack (dextrophenylalanine proline arginine chloromethylketone); anti-
proliferative
agents such as enoxaprin, angiopeptin, monoclonal antibodies capable of
blocking
smooth muscle cell proliferation, hirudin, and acetylsalicylic acid; anti-
inflammatory
agents such as dexamethasone, prednisolone, corticosterone, budesonide,
estrogen,
sulfasalazine, and mesalamine; antineoplastic/antiproliferative/anti-miotic
agents such as
paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones,
endostatin,
angiostatin and thymidine kinase inhibitors; anesthetic agents such as
lidocaine,
bupivacaine and ropivacaine; anti-coagulants such as D-Phe-Pro-Arg
chloromethyl
keton, an RGD peptide-containing compound, heparin, antithrombin compounds,
platelet
receptor antagonists, anti-thrombin antibodies, anti-platelet receptor
antibodies, aspirin,
prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides;
vascular cell
growth promoters such as growth factor inhibitors, growth factor receptor
antagonists,
transcriptional activators, and translational promoters, vascular cell growth
inhibitors
such as growth factor inhibitors, growth factor receptor antagonists,
transcriptional
repressors, translational repressors, replication inhibitors, inhibitory
antibodies,
antibodies directed against growth factors, bifunctional molecules consisting
of a growth
factor and a cytotoxin; bifunctional molecules consisting of an antibody and a
cytotoxin;
cholesterol-lowering agents; vasodilating agents; and agents which interfere
with
endogenous vascoactive mechanisms, and any combinations thereof.
Where an agent includes a genetic therapeutic agent, such a genetic agent
may include but is not limited to: anti-sense DNA and RNA; DNA coding for anti-
sense
RNA, tRNA or rRNA to replace defective or deficient endogenous molecules;
angiogenic factors including growth factors such as acidic and basic
fibroblast growth
factors, vascular endothelial growth factor, epidermal growth factor,
transforming growth
factor a and /3, platelet-derived endothelial growth factor, platelet-derived
growth factor,
tumor necrosis factor a, hepatocyte growth factor and insulin like growth
factor; cell
cycle inhibitors including CD inhibitors, thyridine kinase ("TK") and other
agents useful
for interfering with cell proliferation; at least one of the family of bone
morphogenic
12
CA 02541217 2006-03-31
WO 2005/070335 PCT/US2004/038383
proteins ("BMP's") such as BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7
(OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and
BI\MIP-16. Any of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7; dimeric
proteins such as homodimers, heterodimers, or combinations thereof; alone or
together
with other molecules; molecules capable of inducing an upstream or downstream
effect
of a BMP such as "hedgehog" proteins, or the DNA's encoding them and any
combinations thereof.
Where a therapeutic includes cellular material, the cellular material may
include but is not limited to: cells of human origin (autologous or
allogeneic); cells of
non-human origin (xenogeneic) and any combination thereof. Some examples of
cellular
material include but are not limited to the following:
SP - (side population cells) These cells are thought to be some of the most
primitive
adult stein cells. They are isolated by a specific FACS technique utilizing
the ability
of SP cells to exclude Hoechst dye from the nucleus. In addition to bone
marrow,
SP cells have been isolated from most tissues, including: cardiac and skeletal
muscle. By the more common surface protein identification these cells are Lin
, Sca-
1+, c-Kit+, CD43+, CD45+, CD34"
Liri - (lineage negative cells) This group of cells is isolated from the bone
marrow and
all cells which have differentiated to a specific lineage (e.g. red blood
cells) have
been removed. Therefore leaving all of the stem and progenitor cells. This is
beneficial because all primitive cells remain, but may reduce efficiency by
including
irrelevant, primitive cell types.
Liri CD34" - Although CD34+ cells have received much attention, many articles
have
been published lately which suggest the most primitive bone marrow derived
stem
cells are CD34"
Liri CD34+ - Presence of the cell surface protein CD34 has been used to
identify
hematopoietic stern cells. However, the marker is also present on progenitor
cells
and white blood cells of various levels of maturity.
Lin cKit+ - cKit is the cell surface receptor for stem cell factor, and
therefore a logical
choice for stem cell selection. Most widely studied from bone marrow sources,
but
have also been isolated from the heart.
13
CA 02541217 2006-03-31
WO 2005/070335 PCT/US2004/038383
MSC - (mesenchymal stem cells) Named so because ordinarily these cells
differentiate
into cells of mesenchyrnal tissues (e.g. bone, cartilage, fat), but may also
differentiate into cardiomyocytes under certain conditions. Easily isolated
from
bone marrow and, unlike hematopoietic stem cells, proliferate in vitro. A
subpopulation of MSCs has been shown to self-renew faster and have a greater
potential for multipotential differentiation than the general MSC population.
D.
Prockop from Tulane U. is publishing in this area.
Cord Blood Cells - Derived from the blood remaining in the umbilical vein
following
child birth. This blood has been shown to contain a higher percentage of
immature
stem cells or progenitor cells. Typically, a matched donor must be found for
patients, but a lower incidence of graft versus host disease compared to stem
cell
isolation from adult blood has been reported. Disadvantages include:
insufficient
cell number in small blood volumes, unforeseen congenital defects, and
contamination by mother's blood which is likely not HLA matched.
Cardiac or other tissue derived stem cells - Most work to date has focused on
isolating
stem cells from bone marrow. This is due to extensive work in improving bone
marrow transplants for chemotherapy and leukemia treatments. However, there is
evidence that similar stern cells which can be identified by similar means
(e.g. SP,
cKit) can be isolated from other tissues (e.g. fat, cardiac muscle).
Whole bone marrow - An "it's in there" approach where whole bone marrow
(filtered for
bone particles) is transplanted. Benefits include: little processing, all stem
and
progenitor cells are present, and matrix proteins and growth factors may also
be
present. Downside - if one or two stem cell types are responsible for cardiac
improvement they will only be present in very low numbers.
BM-MNCs - (bone marrow mononuclear cells) Separated from whole bone marrow by
a
density gradient centrifugation procedure, this population contains non-
granular
white blood cells, progenitor cells, and stem cells.
EPCs - (endothelial progenitor cells) Isolated from bone marrow based on cell
surface
markers, these cells will become endothelial cells. In theory, these cells
will form
new blood vessels when delivered to ischemic tissue.
Skeletal myoblasts - (or satellite cells) These cells are responsible for the
regeneration of
14
CA 02541217 2006-03-31
WO 2005/070335 PCT/US2004/038383
skeletal muscle following injury. They have the ability to fuse with other
myoblasts
or damaged muscle fibers. Cardiac muscle therapies assume these cells can
integrate
into the host tissue and improve tissue properties or functionally participate
in
contraction.
MDCs - (muscle derived cells) A population of cells isolated from adult
skeletal muscle
which are similar to myoblasts. The isolation technique preplating entails
collecting
cells which attach to culture dishes at different times after biopsy. Cells
with the
best potential plate in the 6"' group and takes several days to obtain.
Investigators
working with these cells claim they are a refined population of myoblasts and
should
result in higher engraftment efficiencies and efficacious procedures.
Go cells - Recently isolated from adult skeletal muscle, these non-satellite
cells express
GATA-4 and, under certain in vitro growth conditions, progress to
spontaneously
beating cardiomyocyte-like cells.
Endothelial cells - Transplantation of autologous endothelial cells along with
a fibrin
matrix induced angiogenesis and improved cardiac function in an ischemic sheep
model.
Adult cardiomyoc es
Fibroblasts - Easily obtained from adult tissues, fibroblasts may provide
growth factors
or participate in the would healing response. Fibroblast play a critical role
in wound
healing; the synthesis and deposition of extracellular matrix. Fibroblasts
commonly
become contractile in wound healing environments.
Smooth muscle cells - Isolated from arteries, these cells may participate or
encourage
angiogenesis and/or beneficial cardiac remodeling following MI.
MSCs + 5-aza - Culture of mesenchymal stem cells with 5-aza forces
differentiation into
cardiomyocytes. These cells beat spontaneously after treatment.
Adult cardiac fibroblasts + 5-aza - In theory, in vitro treatment of cardiac
fibroblasts with
5-aza will result in differentiation into myogenic cells.
Genetically modified cells - Isolation of cells from the patient and
genetically modifying
them in vitro to encourage production of proteins or differentiation into a
cell type
which will be beneficial for treating heart failure.
Tissue engineered grafts - Isolation of cells from the patient which are then
seeded onto
CA 02541217 2006-03-31
WO 2005/070335 PCT/US2004/038383
and cultured within resorbable scaffolds (e.g. collagen, PLGA). These cell
seeded
constructs are then implanted into the patient.
MyoD scar fibroblasts - MyoD family of transcription factors prompt skeletal
muscle
cell differentiation in fibroblasts. Procedure involves isolation of cardiac
scar
fibroblasts, genetic transfection with MyoD in vitro and delivery of the cells
to the
heart to encourage myogenesis.
Pacing cells - Genetically modified fibroblasts which become electrically
conducting and
signal generators.
Embryonic stem cell clones - Use of cloning technology to produce
cardiomyocytes,
progenitors, or stem cells which are genetically identical to the patient.
Embryonic stern cells - These cells are the most primitive of cells and will
differentiate
into
functional cardiomyocytes under certain conditions. Both political and
technological hurdles must be overcome before commercialization of this
technology.
Fetal or neonatal cells - Isolated from the heart of donors, these cells may
incorporate
into host tissue without immune rejection. Some cardiomyocyte progenitor cells
must be present due to the continued growth of the heart in fetal and neonatal
humans.
Immunologically masked cells - Allogeneic cell sources (e.g. donor
cardiomyocytes) are
currently unfeasible due to immune rejection. However, masking technologies
have
been developed which could make this technology feasible.
Tissue engineered grafts - Isolation of cells from a donor which are then
seeded onto and
cultured within resorbable scaffolds (e.g. collagen, PLGA). These cell seeded
constructs are then implanted into the host or recipient.
Genetically modified cells - Isolation of cells from a donor and genetically
modifying
them in vitro to encourage production of proteins or differentiation into a
cell type
which will be beneficial for treating heart failure. The modified cells will
then be
transplanted into the host or patient.
Teratoma derived cells - A teratocarcinoma is a form of cancer in which the
tumor is
16
CA 02541217 2006-03-31
WO 2005/070335 PCT/US2004/038383
composed of a heterogeneous mixture of tissues. Through isolation of cells
from
this tumor and in vitro manipulation and culture a neuronal cell line has been
developed. Layton Biosciences has successfully used these cells to form new
brain
tissue in stroke patients. Similar techniques may be used to produce a
myogenic cell
line.
Where a therapeutic agent comprises at least one polymer agent or
coating, the at least one coating may include but is not limited to:
polycarboxylic acids;
cellulosic polymers, including cellulose acetate and cellulose nitrate;
gelatin;
polyvinylpyrrolidone; cross-linked polyvinylpyrrolidone; polyanhydrides
including
maleic anhydride polymers; polyamides; polyvinyl alcohols; copolymers of vinyl
monomers such as EVA; polyvinyl ethers; polyvinyl aromatics; polyethylene
oxides;
glycosaminoglycans; polysaccharides; polyesters including polyethylene
terephthalate;
polyacrylamides; polyethers; polyether sulfone; polycarbonate; polyalkylenes
including
polypropylene, polyethylene and high molecular weight polyethylene;
halogenated
polyalkylenes including polytetrafluoroethylene; polyurethanes;
polyorthoesters;
proteins; polypeptides; silicones; siloxane polymers; polylactic acid;
polyglycolic acid;
polycaprolactone; polyhydroxybutyrate valerate and blends and copolymers
thereof;
coatings from polymer dispersions such as polyurethane dispersions (BAYHDROL ,
etc.), fibrin, collagen and derivatives thereof; polysaccharides such as
celluloses,
starches, dextrans, alginates and derivatives; hyaluronic acid; squalene
emulsions;
polyacrylic acid, a copolymer of polylactic acid and polycaprolactone; medical-
grade
biodegradable materials such as PGA-TMC, Tyrosine-Derived Polycarbonates and
aiylates; polycaprolactone co butyl acrylate and other co polymers; Poly-L-
lactic acid
blends with DL-Lactic Acid; Poly(lactic acid-co-glycolic acid);
polycaprolactone co
PLA; polycaprolactone co butyl acrylate and other copolymers; Tyrosine-Derived
Polycarbonates and arylate; poly amino acid; polyphosphazenes;
polyiminocarbonates;
polydimethyltrimethylcarbonates; biodegradable CA/PO4's; cyanoacrylate; 50/50
DLPLG; polydioxanone; polypropylene fumarate; polydepsipeptides;
macromolecules
such as chitosan and Hydroxylpropylmethylcellulose; surface erodible material;
maleic
anhydride copolymers; zinc-calcium phosphate; amorphous polyanhydrides; sugar;
17
CA 02541217 2006-03-31
WO 2005/070335 PCT/US2004/038383
carbohydrate; gelatin; biodegradable polymers; and polymers dissolvable in
bodily fluids;
and any combinations thereof.
In at least one embodiment an example of a suitable polymer agent or
coating comprises block copolymers comprising at least one A block and at
least one B
block. The A blocks are preferably soft elastomeric blocks, which are based
upon one or
more polyolefins, or other polymer with a glass transition temperature at or
below room
temperature. For example, the A blocks can be polyolefinic blocks having
alternating
quaternary and secondary carbons of the general formulation: -(CRR'-CH2)õ-,
where R
and R' are, independently, linear or branched aliphatic groups such as methyl,
ethyl,
propyl, isopropyl, butyl, isobutyl and so forth, or represent cyclic aliphatic
groups such as
cyclohexane, cyclopentane, and the like, either with or without pendant
groups.
CH3
H2C
Preferred polyolefinic blocks include polymeric blocks of isobutylene, CH3,
(i.e.,
polymers where R and R' are methyl groups). Other examples of A blocks include
silicone rubber blocks and acrylate rubber blocks.
The B blocks are preferably hard thermoplastic blocks with glass transition
temperatures significantly higher than the elastomeric A blocks which, when
combined
with the soft A blocks, are capable of, inter alia, altering or adjusting the
hardness of the
resulting copolymer to achieve a desired combination of qualities. Examples of
B blocks
include polymers of methacrylates or polymers of vinyl aromatics. More
specific
examples of B blocks include blocks that are (a) formed from monomers of
styrene
CH=
styrene derivatives (e.g., a-methylstyrene, rinbalhylated styrenes or
ring -halogenated styrenes or other substituted styrenes where one or more
substituents
are present on the aromatic ring) or mixtures of the same, collectively
referred to herein
as "styrenic blocks" or "polystyrenic blocks" or are (b) formed from monomers
of
methylmethacrylate, ethylmethacrylate, hydroxyethyl methacrylate or mixtures
of the
same.
The block copolymers are provided in a variety of architectures, including
cyclic,
linear, and branched architectures. Branched architectures include star-shaped
architectures (e.g., architectures in which three or more chains emanate from
a single
18
CA 02541217 2006-03-31
WO 2005/070335 PCT/US2004/038383
region), comb architectures (e.g., copolymers having a main chain and a
plurality of side
chains), and dendritic architectures (including arborescent or hyperbranched
copolymers).
Some specific examples of such block copolymers include the following: (a) BA
(linear diblock), (b) BAB or ABA (linear triblock), (c) B(AB), or A(BA),
(linear
alternating block), or (d) X-(AB) , or X-(BA) , (includes diblock, triblock
and other
radial block copolymers), where n is a positive whole number and X is a
starting seed, or
initiator, molecule. One specific group of polymers have X-(AB), structures,
which are
frequently referred to as diblock copolymers and triblock copolymers where n=1
and
n=2, respectively (this terminology disregards the presence of the starting
seed molecule,
for example, treating A-X-A as a single A block, with the triblock therefore
denoted as
BAB). A particularly beneficial polymer from this group is polystyrene-
polyisobutylene-
polystyrene triblock copolymer (SIBS). Where n=3 or more, these structures are
commonly referred to as star-shaped block copoly pers. Other examples of block
polymers include branched block copolymers such as dendritic block copolymers,
wherein at least one of the A and B blocks is branched, for instance, where
the A blocks
are branched and are capped by the B blocks.
The inventive medical devices may also be provided with a sugar or more
generally a carbohydrate and/or a gelatin to maintain the inventive medical
devices on a
balloon during delivery of the medical device to a desired bodily location.
Other suitable
compounds for treating the inventive medical devices include biodegradable
polymers
and polymers which are dissolvable in bodily fluids. Portions of the interior
and/or
exterior of the inventive medical devices may be coated or impregnated with
the
compound. Mechanical retention devices may also be used to maintain the
inventive
medical devices on the balloon during delivery.
The inventive medical devices may also be provided in whole or in part
with one or more of the above therapeutic agents, polymeric coatings or the
like. Where
multiple therapeutic agents are provided, different coatings and/or mechanisms
may
release the drugs at different rates. For example, one therapeutic agent may
be released
at a fast rate and another therapeutic agent may be released at a slow rate.
Where
multiple polymeric coatings are provided, the coatings may degrade or erode at
different
19
CA 02541217 2011-07-25
rates.
While reference has been made to various preferred embodiments of the
invention other variations, implementations, modifications, alterations and
embodiments
are comprehended by the broad scope of the appended claims. Some of these have
been
discussed in detail in this specification and others will be apparent to those
skilled in the
art. Those of ordinary skill in the art having access to the teachings herein
will
recognize these additional variations, implementations, modifications,
alterations and
embodiments, all of which are within the scope of the present invention, which
invention
is limited only by the appended claims.
